
Vijaya Diagnostic Centre Q4 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
No
Order
Yes
Capex
Yes
2 of 5 growth signals are positive.
Full analysisRevenue guidance
Category 3- Company expects low single-digit volume growth (around 10-12%) in existing hubs limited by capacity constraints.
- New hubs opening expected to drive faster growth with potential for low double-digit revenue growth once new capacity is added.
- PH Pune business expected to triple revenue in 4-5 years, with 5 new hubs starting over 2 years.
- Organic revenue growth excluding PH Pune around 18.5% year-on-year reported, driven primarily by volume growth (~17%).
- Hyderabad core region showing healthy double-digit growth (~13-14%) in revenue and 11-12% in volume.
- Tier 2 and new geographies showing higher volume growth, around 30-40%, due to capacity expansion.
- Plans to add around 10 hubs in 2 years, with 4-5 in Pune for faster-market growth.
- Overall revenue growth driven both by footfall increases and modest price/mix changes (1-2%).
See what Vijaya Diagnostic Centre management said on margin guidance — free account, 30 seconds.
Fundraise plans
No- No current need for raising debt as the company has a healthy treasury of around INR185 crore.
- Expected free cash flow of INR170-190 crores annually supports upcoming capex requirements.
- Planned capex of INR200-220 crores for new centers in the next 2 years will be funded largely through internal accruals and cash reserves.
- Debt raising will only be considered if inorganic acquisitions are made, but no such plans currently.
- Equity fundraising is not mentioned as a requirement currently.
- Management emphasizes operational scaling and talent acquisition as key constraints rather than capital availability.
See what Vijaya Diagnostic Centre management said on order book — free account, 30 seconds.
Capex plans
Yes- Planned capital expenditure (capex) of INR 200 to 220 crores over the next 2 years.
- Majority of capex aimed at adding about 10 new hubs, with 4 to 5 in Pune and the rest in eastern and core geographies.
- INR 120 crores of the capex expected to be spent in the Pune region, including one flagship hub with PET CT, gamma camera, and state-of-the-art facilities.
- Additional investment planned for adding spokes linked to these hubs, supporting network expansion.
- Some capex reserved for adding new modalities and replacing old equipment (replacement capex of around INR 10-15 crores, over and above INR 220 crores).
- Investments include upgrading IT systems and digital initiatives (~INR 2-3 crores annually).
- Growth-funded primarily from internal accruals and existing cash reserves; no anticipated debt raising required.
- Potential inorganic acquisitions considered if suitable opportunities arise.
Track Vijaya Diagnostic Centre — get its next earnings analysis in your feed
How does Vijaya Diagnostic Centre rank vs peers in Healthcare Services?
Pro featureHow does Vijaya Diagnostic Centre rank in Healthcare Services?
Compare Vijaya Diagnostic Centre against every Healthcare Services company (Q4 FY24) on revenue, margins and earnings-call signals.
Continue your research
What Vijaya Diagnostic Centre's management said in earlier quarters
Others in Healthcare Services this season
- Chandan Healthca (Q2 FY27)
Q2 FY27 operating income: ₹57.94 Cr, up 45.04% YoY from ₹39.95 Cr (Page 8) . Key investor presentation takeaways from Chandan Healthcare Ltd's Q2 FY27 investor
- Invicta Diagnostic (Q2 FY27)
Revenue from operations for the half year ended September 30, 2026: ₹379.11 lakhs (Page 4). Key results statement takeaways from Invicta Diagnostic Ltd's Q2 FY2
- Unihealth Hosp (Q2 FY27)
1,270 million with a year-on-year (YoY) growth of 6.3% . Key results statement takeaways from Unihealth Hospitals Ltd's Q2 FY27 results statement — and how it r
- Sangani Hospital (Q2 FY27)
1008.56 lakhs (~11.8% increase). Key results statement takeaways from Sangani Hospitals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.